Core Viewpoint - Quantum BioPharma Ltd. announced that its subsidiary, Unbuzzd Wellness Inc., is launching a Regulation D 506(c) offering to raise up to US$5 million for growth and a potential initial public offering, which will not dilute Quantum BioPharma shareholders [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has an agreement for royalty payments of 7% of sales from Unbuzzd until total payments reach US$250 million, after which the royalty rate drops to 3% [6]. Product Information - Unbuzzd is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, developed by a team with expertise in pharmacology and medicine [8][9]. - Clinical trials have shown that Unbuzzd can reduce blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, improve alertness, and lessen hangover symptoms significantly [10][13]. Capital Raising Strategy - Unbuzzd has partnered with MZ Digital and Dealmaker to conduct the capital raise campaign, allowing investments through traditional and cryptocurrency payments [3]. - The offering aims to support direct-to-consumer, distributor, and retail expansion plans for Unbuzzd [5].

Core Insights - Quantum BioPharma Ltd. has engaged MZ Digital and Dealmaker to raise up to US$5 million through a Regulation D 506(c) offering for Unbuzzd Wellness Inc., which produces a beverage that accelerates alcohol metabolism and reduces hangover symptoms [1][2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - Unbuzzd Wellness Inc. is a public issuer that offers a scientifically backed beverage designed to help alcohol consumers manage their consumption and recovery [5] Product Details - Unbuzzd is a proprietary blend of vitamins, minerals, and herbs that aids in faster alcohol metabolism, restores mental clarity, and improves cognition [5] - Clinical trials have shown that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, with significant improvements in alertness and reduced hangover symptoms [6][7][14] Financial Aspects - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on sales until reaching $250 million, after which the royalty rate drops to 3% [3]

Core Viewpoint - Quantum BioPharma Ltd. announces the hiring of MNP LLP for PCAOB audits of Unbuzzd Wellness Inc. in preparation for a potential IPO, following the resignation of the previous auditor [1][2][3] Group 1: Company Developments - Unbuzzd Wellness Inc. has changed its name from Celly Nutrition Corp. effective May 23, 2025, with new CUSIP and ISIN numbers assigned [4] - The company is a non-trading but fully reporting public issuer focused on wellness and recovery supplements, specifically the unbuzzd beverage that aids in alcohol metabolism [8][9] - Unbuzzd has been scientifically validated through a double-blind, randomized, placebo-controlled clinical trial, demonstrating its effectiveness in accelerating alcohol metabolism and reducing hangover symptoms [9] Group 2: Financial and Audit Information - MNP LLP, a PCAOB-registered audit firm, has been engaged to conduct audits for Unbuzzd Wellness Inc. to ensure compliance and readiness for a possible IPO [2][3] - The previous auditor, Stern & Lovrics LLP, resigned at the company's request, and MNP was appointed based on the audit committee's recommendation [1][3] - There were no reservations or modified opinions in the previous auditor's reports, indicating a clean audit history for the most recent financial year [3] Group 3: Leadership and Strategic Direction - John Duffy, CEO of Unbuzzd Wellness Inc., emphasizes the importance of MNP's engagement in adhering to industry standards and preparing for the IPO [3] - Gerry David, Board Co-Chair, highlights the completion of PCAOB audits as a crucial step in raising capital and considering an IPO [3] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments from unbuzzd sales until a total of $250 million is reached [6]

Core Viewpoint - Quantum BioPharma Ltd. announces the hiring of MNP LLP for PCAOB audits of Unbuzzd Wellness Inc. in preparation for a potential IPO, following the resignation of the previous auditor [1][2][3] Group 1: Company Developments - Unbuzzd Wellness Inc. has engaged MNP LLP to conduct PCAOB audits effective May 20, 2025, to ensure compliance and readiness for a possible IPO [1][2] - The company has changed its name to Unbuzzd Wellness Inc. effective May 23, 2025, with new CUSIP and ISIN numbers assigned [4][5] - There were no reservations or modified opinions in the previous auditor's reports, indicating a clean audit history [3] Group 2: Product Information - Unbuzzd is a scientifically-proven beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, appealing to a broad audience of alcohol consumers [8][9] - The product has been validated by a double-blind, randomized, placebo-controlled clinical trial, demonstrating its effectiveness in speeding up alcohol metabolism and reducing symptoms of intoxication [9] Group 3: Leadership Insights - John Duffy, CEO of Unbuzzd Wellness Inc., emphasizes the importance of MNP's engagement in adhering to industry standards and preparing for the IPO [3] - Gerry David, Board Co-Chair, highlights the completion of PCAOB audits as a crucial step in raising capital and considering an IPO [3] Group 4: Ownership and Financial Structure - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments from sales until reaching $250 million, after which the royalty rate will drop to 3% [6]

Core Viewpoint - Quantum BioPharma Ltd. announced the launch of its anti-hangover beverage, unbuzzd, in Puerto Rico through its licensee Celly Nutrition and distribution partner FUSION Distribution Group, aiming to expand its market presence in the Caribbean region [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse [11]. - Celly Nutrition Corporation is a public issuer specializing in wellness and recovery supplements, with unbuzzd developed by a team in pharmacology and medicine [7]. - FUSION Distribution Group is a leading distributor of health-conscious food and beverages in Puerto Rico and the Caribbean, with a strong network including major retailers [4][6]. Product Details - unbuzzd is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms, supported by a double-blind placebo-controlled study [3][8]. - The product is available in convenient "On-the-Go Powder Stick Packs" and can be purchased in various pack sizes [9]. Distribution Strategy - FUSION will distribute unbuzzd across various retail channels in Puerto Rico, including grocery stores, pharmacies, and hospitality venues, aiming for widespread consumer accessibility [5][4]. - The partnership with FUSION is seen as a significant milestone for Celly Nutrition in expanding unbuzzd's retail availability [5]. Financial Arrangement - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and will receive a 7% royalty on unbuzzd sales until reaching $250 million, after which the royalty will decrease to 3% [11].